Rani Therapeutics Holdings, Inc. Class A Common Stock
RANIRani Therapeutics Holdings, Inc. Class A (RANI) is a biopharmaceutical company focused on developing oral biologic delivery platforms. Their flagship technology involves using an ingestible, self-orienting robotic pill to deliver biologic drugs orally, aiming to replace injections for various conditions. The company is committed to advancing innovative drug delivery solutions to improve patient experiences and treatment outcomes.
Company News
Rani Therapeutics announced a $20 million registered direct offering of Class A common stock at $1.07 per share, along with pre-funded warrants, led by a sovereign wealth fund and other healthcare-focused investors. The offering is expected to close on May 27, 2026. The company is a clinical-stage biotherapeutics firm developing oral delivery tec...
Rani Therapeutics announced the appointment of Jesper Høiland as Head of Strategy, a newly created role. Høiland, who has served as a strategic adviser since 2023, brings over 30 years of pharmaceutical leadership experience, including expertise in obesity and metabolic disease. He will be responsible for shaping corporate and pipeline strategy...
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These confer...
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’...
